Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

A fixed-duration, chemo-sparing approach in CLL: 8-year results of the phase 2 icll-07 filo trial

View Full Paper
Ask AI
Bookmark
Share

Authors

AMAnne‐Sophie MichalletMGMagali Le Garff‐TavernierMDMarie Sarah Dilhuydy

Discussion

Loading...

Member takes

Overview

Phase 2 trial demonstrates 87% progression-free survival in chronic lymphocytic leukemia patients, indicating a promising chemo-sparing approach.

Key Points

  • Eighty-seven percent of patients achieved progression-free survival after fixed-duration treatment.
  • Overall survival rate reached 93% among chronic lymphocytic leukemia patients with a median follow-up of 97 months.
  • Analysis of the ICLL-07 trial revealed significant long-term outcomes with minimal serious infections reported.
  • No increased risks were observed for second cancers among patients after treatment completion.

Cite This Study

Michallet et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d866https://doi.org/10.1182/blood-2025-3883
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1FCR-I/iven combination for CLL: «Cheap but fierce»2025
  2. 2Fixed-duration versus continuous targeted treatment for previously untreated chronic lymphocytic leukemia: Results from the randomized CLL17 trial2025 · 4 citations
  3. 3Ibrutinib plus R-CHOP followed by maintenance in untreated ABC-DLBCL patients with IPI ≥2: A first analysis of phase II Study  FIL_RI-CHOP2025
  4. 4Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLL2025
  5. 5Mutation-guided finite-duration acalabrutinib plus venetoclax for relapse after first-line finite-duration COVALENT Bruton tyrosine kinase inhibitor plus venetoclax‒based combination therapy in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma: Phase 2 MAVRiC study2025